India, May 13 -- Shares of HCW Biologics Inc. (HCWB) gained over 150% on Tuesday morning after the clinical-stage biopharmaceutical company announced positive results of studies of proprietary fusion protein, HCW9206 and availability for commercialization.
HCWB is currently trading at $13.26, up $7.97 or 150.66%, on a heavy volume of 16 million shares, above average volume of 13 thousand, on the Nasdaq. The stock opened its trading at $15.00 after closing Monday at $5.29. The stock has traded between $5.00 and $100.80 in the past 52-week period.
HCW9206 is a novel class of immunotherapeutic that enables a single molecule to deliver synergistic signals from three different immune-stimulatory cytokines.
googletag.cmd.push(function() { goog...